Verucerfont is primarily investigated for its potential therapeutic applications in the treatment of stress-related disorders, particularly those involving the dysregulation of the corticotropin-releasing factor (CRF) system. It acts as a CRF1 receptor antagonist, which plays a key role in the body's stress response. By blocking this receptor, it may help reduce symptoms of anxiety, depression, and other stress-related conditions. Clinical studies have explored its efficacy in managing conditions like generalized anxiety disorder and major depressive disorder, offering a novel approach to modulating the stress pathway. Additionally, it has been studied for its potential in addressing substance abuse disorders, as stress is a significant factor in relapse. Its application could provide a targeted treatment option for patients who do not respond adequately to traditional therapies.